Literature DB >> 27591066

Deep brain stimulation for levodopa-refractory benign tremulous parkinsonism.

Takuya Konno1, Owen A Ross2, Robert E Wharen3, Ryan J Uitti1, Zbigniew K Wszolek4.   

Abstract

Benign tremulous parkinsonism (BTP) is characterized by prominent resting tremor combined with action and postural components, and with only subtle rigidity and bradykinesia. This tremor is frequently disabling and poorly responsive to therapy with levodopa. Thus, BTP could be considered either as a distinct clinical disorder or a variant of PD. We present a case of a 57-year-old man who had a 3-year history of severe and functionally disabling resting tremor with action and postural features bilaterally but with left dominant hand predominance. There was only very mild rigidity and bradykinesia and no postural instability. His tremor was refractory to dopaminergic therapy, including carbidopa/levodopa. The dopamine transporter (DAT) imaging showed reduced tracer uptake in the putamen bilaterally, more so on the right side. He was treated with deep brain stimulation (DBS) targeting the right ventral intermediate nucleus of the thalamus. His tremor resolved immediately after procedure. The DAT imaging abnormalities indicate the presynaptic dopamine deficiency. In some autopsied BTP cases classic alpha-synuclein pathology of PD was observed. Thus, despite the lack of levodopa responsiveness BTP likely represents a variant of PD and not a distinct neurodegenerative disorder. DBS should be considered for patients with BTP PD variant despite their poor responsiveness to levodopa treatment.
Copyright © 2016 Polish Neurological Society. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.

Entities:  

Keywords:  Benign tremulous parkinsonism; Deep brain stimulation; Dopamine transporter imaging; Parkinson's disease; Tremor

Mesh:

Substances:

Year:  2016        PMID: 27591066      PMCID: PMC5012306          DOI: 10.1016/j.pjnns.2016.05.008

Source DB:  PubMed          Journal:  Neurol Neurochir Pol        ISSN: 0028-3843            Impact factor:   1.621


  8 in total

1.  Benign tremulous parkinsonism: a clinicopathological study.

Authors:  Ali H Rajput; Christopher A Robinson; Alexander H Rajput
Journal:  Mov Disord       Date:  2008-01-30       Impact factor: 10.338

2.  Benign tremulous parkinsonism in a patient with dardarin mutation.

Authors:  Giovanni Rizzo; Sara Marconi; Sabina Capellari; Cesa Scaglione; Paolo Martinelli
Journal:  Mov Disord       Date:  2009-07-15       Impact factor: 10.338

3.  Neuropathological findings in benign tremulous parkinsonism.

Authors:  Marianna Selikhova; Peter A Kempster; Tamas Revesz; Janice L Holton; Andrew J Lees
Journal:  Mov Disord       Date:  2012-12-12       Impact factor: 10.338

4.  Deep brain stimulation in benign tremulous parkinsonism.

Authors:  Rodolfo Savica; Joseph Y Matsumoto; Keith A Josephs; J Eric Ahlskog; Matt Stead; Kendall H Lee; Bryan T Klassen
Journal:  Arch Neurol       Date:  2011-08

Review 5.  Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues.

Authors:  Jeff M Bronstein; Michele Tagliati; Ron L Alterman; Andres M Lozano; Jens Volkmann; Alessandro Stefani; Fay B Horak; Michael S Okun; Kelly D Foote; Paul Krack; Rajesh Pahwa; Jaimie M Henderson; Marwan I Hariz; Roy A Bakay; Ali Rezai; William J Marks; Elena Moro; Jerrold L Vitek; Frances M Weaver; Robert E Gross; Mahlon R DeLong
Journal:  Arch Neurol       Date:  2010-10-11

6.  Benign tremulous parkinsonism.

Authors:  Keith A Josephs; Joseph Y Matsumoto; J Eric Ahlskog
Journal:  Arch Neurol       Date:  2006-03

7.  [Successful treatment with bilateral deep brain stimulation of the subthalamic nucleus for benign tremulous parkinsonism].

Authors:  Jiro Fukae; Chikashi Fukaya; Hideki Oshima; Kenji Ishii; Yoshio Tsuboi; Yoichi Katayama; Nobutaka Hattori
Journal:  Rinsho Shinkeigaku       Date:  2014

8.  Tremor dominant parkinsonism: Clinical description and LRRK2 mutation screening.

Authors:  Jordi Clarimón; Javier Pagonabarraga; Coro Paisán-Ruíz; Antonia Campolongo; Berta Pascual-Sedano; José-Félix Martí-Massó; Andrew B Singleton; Jaime Kulisevsky
Journal:  Mov Disord       Date:  2008-03-15       Impact factor: 10.338

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.